Payment overview · 2025
General Payments
$145.59
9 reported records · 6 companies
Healthcare provider profile · identity verified
Gurdip Singh Flora, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · SIMI VALLEY, CA · NPI 1164611075
Verified facts
What the public records show
CMS Open Payments records show Gurdip Singh Flora, M.D received $145.59 in general payments during 2025 across 9 reported records.
Viatris Specialty LLC accounted for 39.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $57.95 | 39.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.35 | 22.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.78 | 12.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.19 | 10.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.12 | 9.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.20 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $145.59 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $57.95 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
125 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 552 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 434 | 113 |
| Losartan Potassium | Losartan Potassium | 289 | 85 |
| Metformin Hcl | Metformin Hcl | 284 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 70 |
| Omeprazole | Omeprazole | 252 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 235 | 57 |
| Eliquis | Apixaban | 208 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 47 |
| Prednisone | Prednisone | 191 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 56 |
| Furosemide | Furosemide | 168 | 47 |
| Tramadol Hcl | Tramadol Hcl | 163 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 154 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 36 |
| Alprazolam | Alprazolam | 150 | 29 |
| Dexlansoprazole Dr | Dexlansoprazole | 149 | 34 |
| Finasteride | Finasteride | 148 | 36 |
| Carvedilol | Carvedilol | 147 | 36 |
| Montelukast Sodium | Montelukast Sodium | 143 | 38 |
| Gabapentin | Gabapentin | 142 | 32 |
| Simvastatin | Simvastatin | 141 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 32 |
| Allopurinol | Allopurinol | 127 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 29 |
| Linzess | Linaclotide | 125 | 17 |
| Lisinopril | Lisinopril | 123 | 29 |
| Azithromycin | Azithromycin | 117 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 22 |
| Clonidine Hcl | Clonidine Hcl | 108 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 33 |
| Famotidine | Famotidine | 106 | 26 |
| Januvia | Sitagliptin Phosphate | 105 | 25 |
| Levofloxacin | Levofloxacin | 104 | 73 |
| Potassium Chloride | Potassium Chloride | 102 | 28 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 101 | 12 |
| Clonazepam | Clonazepam | 99 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 99 | 13 |
| Ozempic | Semaglutide | 87 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 81 | 13 |
| Trazodone Hcl | Trazodone Hcl | 81 | 18 |
| Donepezil Hcl | Donepezil Hcl | 79 | 18 |
| Alendronate Sodium | Alendronate Sodium | 77 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 75 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 11 |
| Glipizide | Glipizide | 72 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 25 |
| Xarelto | Rivaroxaban | 71 | suppressed |
| Levetiracetam | Levetiracetam | 70 | 16 |
| Baclofen | Baclofen | 69 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 34 |
| Ibandronate Sodium | Ibandronate Sodium | 64 | 11 |
| Meloxicam | Meloxicam | 64 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 61 | 15 |
| Hydrocortisone | Hydrocortisone | 61 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 61 | suppressed |
| Atenolol | Atenolol | 58 | 15 |
| Glimepiride | Glimepiride | 56 | suppressed |
| Lorazepam | Lorazepam | 56 | 19 |
| Mirtazapine | Mirtazapine | 56 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 53 | 45 |
| Nystatin | Nystatin | 52 | 21 |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 51 | suppressed |
| Brilinta | Ticagrelor | 49 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 46 | 11 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | 14 |
| Methylprednisolone | Methylprednisolone | 43 | 31 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | 14 |
| Diazepam | Diazepam | 40 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | 12 |
| Temazepam | Temazepam | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 13 |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Valsartan | Valsartan | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | suppressed |
| Novolog | Insulin Aspart | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 20 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 29 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 11 |
| Humulin R | Insulin Regular, Human | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Transderm-Scop | Scopolamine | 27 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Budesonide | Budesonide | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Gentamicin Sulfate | Gentamicin Sulfate | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Multaq | Dronedarone Hcl | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Sulfasalazine | Sulfasalazine | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Procrit | Epoetin Alfa | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 11 |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Primidone | Primidone | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Klor-Con | Potassium Chloride | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $145.59 · 9 records | Viatris Specialty LLC | AVYCAZ, DALVANCE, JOURNAVX, MOUNJARO, TRELEGY ELLIPTA, VOQUEZNA, YUPELRI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error